Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Leuk Res. 2015 Feb 7;39(5):495–500. doi: 10.1016/j.leukres.2015.02.001

Table 1. Patient Characteristics in the ITT population.

Characteristic (n) ITT Population (n = 165)
Number %
Age, years (standard deviation) 60.8 (9.5)
Male Gender 128 78
Race
 Caucasian 148 90
 Black 10 6
 Asian 1 1
 Other 6 4
Creatinine Clearance (mL/min, 159) 98.2 (34.7)
 ≥ 30 - < 50 6 4
 ≥ 50 - ≤ 80 50 31
 > 80 103 65
ECOG Performance Status (159)
 0 65 41
 1 74 47
 2 20 13
Rai Stage (150)
 I, II 29 19
 III, IV 121 81
Binet Stage (109)
 A 3 3
 B, C 106 97
Bulky Lymphadenopathya 115 70
Cytogenetic Abnormalitiesb
 del(17p) (141) 49 35%
 del(11q) (145) 43 31%
Number of prior therapies (range) 4 (1 – 12)
Prior Therapies
 Alkylating agent 163 99
 Fludarabine 165 100
 Rituximab 143 87
 Alemtuzumab 62 38
 Fludarabine refractory 158 96
a

Defined as at least 1 lymph node > 5 cm in longest diameter by cross sectional imaging at study registration.

b

Classified according to Döhner, et al31.